CRSP vs VCEL
CRSP: CRISPR Therapeutics is a biopharmaceutical company pioneering gene-editing therapies to treat and potentially cure severe genetic diseases using its proprietary CRISPR/Cas9 technology. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | CRSP | VCEL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $46.73 | $45.32 | |
| Market cap as of 2026-08-03 | $4.5B | $2.3B | |
| P/E as of 2026-08-03 | n/a | 109.36 | |
| PEG as of 2026-08-03 | -0.21 | 0.38 | CRSP lower |
| Net margin as of 2026-08-03 | -13856.5% | +7.3% | VCEL higher |
| Gross margin as of 2026-08-03 | n/a | +74.8% | |
| Operating margin as of 2026-08-03 | -15754.2% | +5.4% | VCEL higher |
| ROE as of 2026-08-03 | -30.9% | +6.4% | VCEL higher |
| ROA as of 2026-08-03 | -24.5% | +4.6% | VCEL higher |
| Debt / equity as of 2026-08-03 | 0.32 | 0.00 | VCEL lower |
| Revenue growth (YoY) as of 2026-08-03 | -89.1% | +22.4% | VCEL higher |
| Revenue CAGR (3y) SEC XBRL | +43.1% | +18.9% | CRSP higher |
| Beta as of 2026-08-03 | 1.77 | 1.07 | |
| 1-year return as of 2026-07-27 close | -27.8% | +13.0% | VCEL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.